Where to for pelvic organ prolapse treatment after the FDA pronouncements? | Zendy

J. M. van Geelen | Zendy; P. L. Dwyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Where to for pelvic organ prolapse treatment after the FDA pronouncements?

Author(s) -

J. M. van Geelen,

P. L. Dwyer

Publication year - 2013

Publication title -

international urogynecology journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.933

H-Index - 92

eISSN - 1433-3023

pISSN - 0937-3462

DOI - 10.1007/s00192-012-2025-3

Subject(s) - medicine , pessary , patient satisfaction , native tissue , surgery , randomized controlled trial , uterine prolapse , medline , clinical trial , surgical mesh , general surgery , hernia , political science , law , tissue engineering , biomedical engineering

With the publication of the updated US Food and Drug Administration (FDA) communication in 2011 on the use of transvaginal placement of mesh for pelvic organ prolapse (POP) it is appropriate to now review recent studies of good quality on POP to assess the safety and effectiveness of treatment options and determine their place in management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research